spacer
home > ict > spring 2016 > editorial comment
PUBLICATIONS
International Clinical Trials

Editorial Comment

It is always interesting to read articles looking at two different sides of the same coin. In this issue, we have a paper from Jens Puhle at 8MAN which discusses how intellectual property is the lifeblood of the pharmaceutical industry, and how the ability to keep data relating to intellectual property hidden from rival organisations is essential in this highly competitive world. Puhle warns that data theft caused by hackers may be only one of the threats that companies should be aware of, and that they should actually be looking closer to home. He reports on GlaxoSmithKline and other businesses that have recently had employees indicted for fraud, and discusses how strict access control and monitoring of staff may be necessary to prevent the theft of research data that could make or break a business.

The other side of this coin is examined by Graham Donaldson at TRAC Services, with respect to clinical trial data which the EMA is attempting to make much more transparent – especially in regards to the new EU Clinical Trial Regulation. He notes that releasing information about the development and registration of medicines in the public domain is required to make sure the regulatory process is trusted, and decision-makers are well-informed. Thus, a balanced approach is necessary when discussing disclosure of European medical research. The article also explores various attitudes from regulatory authorities towards data transparency, and highlights the EMA’s approach to moving forward.

A couple of papers in this edition look at different aspects of oncology and clinical trials to develop drugs in that indication. Dr Don Gabriel of United BioSource Corporation considers the implications of pharmacogenetics – the study of individuals’ genetic variations on clinical studies – and explains how these can relate to oncology in particular. We are used to hearing that personalised medicine – now perhaps more properly called precision medicine – is an ever-growing area of interest, and essential to each individual’s genomic make-up. The article discusses how pharmacogenetics is redefining the approach to drug development, especially in oncology with relation to diagnosis and classification, treatment regimes and posttreatment monitoring of patients.

Dr Martin Lachs at ICON investigates a more practical aspect of running clinical trials in cancer patients. He observes that few patients in both the US and the UK have access to clinical trials or, perhaps more accurately, avail themselves of the opportunity to take part in them. He believes that the relationship between investigators and service providers is crucial in running successful trials, and looks at many of the aspects of the process of running the study – including scientific, structural, financial and cultural aspects – before examining the role CROs can play in a trial.

Finally, I would like to highlight the paper by Dr Graham Wylie at MRN, who discusses the fact that paediatric trials have become considerably more common as a result of governmental and regulatory pressures. He notes that these trials present a huge challenge from both scientific and ethical points of view. A specific aspect of the trial methodology is the increasing use of home healthcare services, and he examines how these may be increasingly applied in running paediatric trials in the future, as patient experience becomes an ever-more important factor.

I hope you enjoy the rest of the magazine and will consider contributing an article yourself!

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

New awards celebrate innovation in sustainable pharmaceutical packaging, winners announced at Connect in Pharma

17 June 2022 / Sciad Newswire / YewMaker and Connect in Pharma announce today that the winners of the new Sustainable Medicines Packaging Awards will be announced at an in-person champagne ceremony at the Connect In Pharma event in Geneva on 14 September 2022.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement